trial

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCTId NCT06191965
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Recruiting
Enrollment 100 (estimated)
Sponsored by Mclean Hospital
Primary completion 2027-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Recruiting
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-06-01
Primary completion
2027-01-31
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
MitoQ

Sponsors

Mclean HospitalLead Sponsor
Yale UniversityCollaborator
University of Lausanne HospitalsCollaborator

Investigators

1
Dost Ongur, MD, PhDPrincipal Investigator

Sites

3 total
New Haven, United StatesBelmont, United StatesLausanne, Switzerland

Linked catalysts

1
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunct — primary completion2027-01-31

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE2,PHASE3
Primary Completion Date
2027-01-31
Status
RECRUITING
relationships
The graph out of here
drug
MitoQ
drug
lead_sponsor
Mclean Hospital
company
collaborator
Yale University
company
University of Lausanne Hospitals
company
indication
Cognitive Dysfunction
indication
Schizophrenia and Related Disorders
indication
Schizophrenia
indication
investigator
Dost Ongur, MD, PhD
person